Gilead is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicine with focus on virology, hepatology, hematology, oncology, cardiovascular, inflammation and respiratory diseases.
The company recorded sales of $30.4 billion in 2016 a decrease by 7% compared to $32.6 billion in 2015 primarily due to a decrease in antiviral product sales. The earnings per share in 2016 was $10.1. The pharmaceutical sales in fiscal year 2016 was $29.9 billion, a decline by 7% from $32.1 billion in 2015 offset by decreases in sales of tenofovir disoproxil (TDF)- based products. The declines were also due to lower sales of Harvoni and Sovaldi, partially offset by sales of Epclusa, which was launched in 2016 across various locations. The fiscal fourth quarter (Q4) sales were $7.3 billion, a decrease of -14% compared to 2015 Q4 sales with earnings per share at $2.36. The pharmaceutical product sales for the company was recorded at $7.2 billion in comparison with $8.4 billion in 2015 resulting in declined growth due to increase in operational expense and low sales of antiviral product segment.
Strategic highlights: (Q4, 2016)
Submitted a New Drug Application to the U.S. FDA for an investigational for sofosbuvir, velpatasvir and voxilaprevir for the treatment of direct-acting antiviral-experienced chronic hepatitis C virus-infected patients. (Dec)
Received approval from Japanese Ministry of Health, Labour and Welfare for Vemlidy (tenofovir alafenamide) treatment for suppression of viral replication in chronic hepatitis B patients. (Dec)
U.S. FDA approved Vemlidy (tenofovir alafenamide) a once-daily treatment for adults with chronic hepatitis B virus infection with compensated liver disease. (Nov)
Committee for Medicinal Products for Human Use, EMA, has adopted a positive opinion Marketing Authorization Application for Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis B virus infection. (Nov)
Check out all the other “Pharma Companies at a Glance” already available. Many more coming next on IgeaHub.